Contraception
RSSArticles
-
Medication Abortion Through Telehealth Is Safe, Effective, and Convenient
Researchers began studying the safety and effectiveness of telehealth medication abortions in 2021 and concluded in 2022 before the U.S. Supreme Court decision to overturn Roe v. Wade. The recently published results showed that telehealth medication abortions are safe, with outcomes of 99.8% without serious adverse events.
-
OB/GYNs Experiencing High Levels of Moral Distress
An OB/GYN was asked by researchers how it felt to work in an abortion-ban state after the U.S. Supreme Court overturned Roe v. Wade — the physician’s response was shocking. The OB/GYN said working in a war zone with actual risk to one’s life was not as distressing as working with patients in an abortion-ban state where the physician continually feared arrest or patient death.
-
Telehealth Medication Abortion Remains Under Threat Even as Access Expands
In June, the U.S. Supreme Court is expected to decide the fate of the abortion medication mifepristone — a decision that could undermine access to the medication at a time when major pharmacies and retailers have begun to offer the pill. Abortion rights advocates, reproductive health clinicians, and others are bracing for a decision that could upend access to safe, legal self-managed abortions for most or all women in the nation.
-
Opill Rollout Includes Major Pharmacies and Retailers — but Price Tag Needs Work
The rollout of the nation’s first over-the-counter birth control pill, Opill, is a major step toward improving contraception access across the United States. But some obstacles remain, including cost and access for minors in places hostile to reproductive autonomy.
-
Beliefs About Women’s Virtue and Chastity May Play a Role in Latina Risk Behaviors
The authors of a recent study revealed that endorsement of certain marianismo beliefs, related to women acting virtuous and chaste, may promote abstinence, but also are associated with sexual risk behaviors.
-
Research Confirms the Value of Title X for Improving Contraception Access
Clients of Title X programs have greater access to a wide range of contraceptive methods, although reach has been limited by federal funding, state laws, and the Trump-era gag rule. A study revealed that people receiving contraception care from non-Title X clinics had lower proportions of receiving long-acting reversible contraception methods, nonoral hormonal methods, and extended supplies of oral contraceptives.
-
State Laws and Court Decisions Bring More Uncertainty to Reproductive Health
In recent months, abortion-ban states have seen even more drastic bills and changes to their citizens’ reproductive health and lives. While abortion bans have closed clinics and prevented physicians from providing standard care to women experiencing pregnancy crises, the states have gone even further, now threatening contraceptives and fertility treatment.
-
New Research on Advance Provision Reveals Interest and Use in United States Since 2022
Interest in advance provision of abortion medication was high even before the U.S. Supreme Court overturned Roe v. Wade, according to recent research. Many of those interested in advance provision were more likely to be highly motivated to prevent pregnancy. They had been using highly effective contraceptives, were well-educated, had private insurance, and were not poor.
-
As Uncertainty Looms, More People Request Advance Provision of Mifepristone
Interest in advance provision of abortion medications mifepristone and misoprostol has increased dramatically in the post-Roe era. It remains popular as a U.S. Supreme Court case looms over whether mifepristone should remain available. Advance provision is one tool to help expand access to the medication.
-
Improve Screening and Retesting for Trichomoniasis
Infection by the protozoan Trichomonas vaginalis is the most common nonviral sexually transmitted infection, with an estimated 6.8 million cases in the United States annually. It can go undiagnosed because most infected people (up to three out of four) do not experience symptoms. Left undiagnosed and untreated, trichomoniasis can increase the risk of pelvic inflammatory disease, infertility, and acquiring HIV and other STIs.